PR Newswire
LONDON, United Kingdom, November 29
29 November 2024
4basebio plc
(“4basebio” or the "Company")
Director’s Dealing
29 November 2024 – 4basebio PLC (AIM: 4BB) (“4basebio” or the “Company”), which develops and commercialises the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, announces that it was informed by Dr. Heikki Lanckriet , CEO of the Company, that he acquired ordinary shares in the Company through the market as follows:
| Name | Number of Shares Acquired | Price per Share (p) | Shareholding Following Acquisition | Shareholding as a Percentage of Issued Share Capital |
| Heikki Lanckriet | 12,000 | 1,315p | 1,115,288 | 7.27% |
The issued share capital of the Company comprises 15,477,395 ordinary shares.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310.
Enquiries
| 4basebio PLC Dr. Heikki Lanckriet |
+44 (0)1223 967 943 |
| Nominated Adviser Cairn Financial Advisers LLP Jo Turner / Sandy Jamieson / Ed Downes |
+44 (0)20 7213 0880 |
| Joint Corporate Broker RBC Capital Markets Rupert Walford / Kathryn Deegan |
+44 (0)20 7653 4000 |
| Joint Corporate Broker Cavendish Capital Markets Limited Geoff Nash / Nigel Birks |
+44 (0)20 7220 0500 |
Notes to Editors
About 4basebio
4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a. | Name | Dr. Heikki Lanckriet | |||
| 2 | Reason for notification | ||||
| a. | Position/Status | CEO | |||
| b. | Initial notification/ Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a. | Name | 4basebio plc | |||
| b. | LEI | 213800E2DX9EAIUNCB30 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a. | Description of the financial instrument, type of instrument Identification Code |
Ordinary Shares ISIN: GB00BMCLYF79 |
|||
| b. | Nature of the transaction | Acquisition of ordinary shares | |||
| Price(s) per share (p) | Volume(s) | ||||
| 1,315p | 12,000 | ||||
| d. | Aggregated information
|
|
|||
| e. | Date of the transaction | 28/11/2024 | |||
| f. | Place of the transaction | London Stock Exchange, AIM | |||
